TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Arco Lab now holds a 50% stake in Neviton
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Subscribe To Our Newsletter & Stay Updated
